Skip to content
Disclosery

Pivotal bioVenture Partners Investment Advisor LLC

Follow

13F filer, CIK 1844645, SAN FRANCISCO, CA

Pivotal bioVenture Partners Investment Advisor LLC reported $172,983,714 across 10 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-13.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001012975-25-000748

Period
2025-09-30
Reported value
$173M
Holdings
10
Top 10 weight
100%
New
1
Sold out
3

Part of the filer group Pivotal bioVenture Partners Investment Advisor LLC

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
IMNMnew+502,512$5.88M
PCVXadded+67,300$2.42M
TRVIadded+110,672$1.01M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
INOZYME PHARMA INCexited-4,494,851-$18M
VIGIL NEUROSCIENCE INCexited-560,595-$4.46M
IOBTQexited-864,197-$1.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001012975-25-000748, largest first. % of portfolio is the value over $172,983,714, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 639,539 shares; 2024Q4: 703,834 shares; 2025Q1: 710,734 shares; 2025Q2: 1,305,125 shares; 2025Q3: 1,372,425 shares 1,372,425$49.4M28.58%+67,300Timeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,595,918 shares; 2024Q4: 1,737,696 shares; 2025Q1: 2,300,774 shares; 2025Q2: 2,300,774 shares; 2025Q3: 2,300,774 shares 2,300,774$40.4M23.38%0Timeline
ARQTARCUTIS BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,120,508 shares; 2024Q4: 2,120,508 shares; 2025Q1: 2,120,508 shares; 2025Q2: 2,120,508 shares; 2025Q3: 2,120,508 shares 2,120,508$40M23.11%0Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 650,695 shares; 2024Q4: 736,645 shares; 2025Q1: 736,645 shares; 2025Q2: 779,045 shares; 2025Q3: 779,045 shares 779,045$17.3M10%0Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,146,110 shares; 2025Q3: 1,256,782 shares 1,256,782$11.5M6.65%+110,672Timeline
IMNMIMMUNOME INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 502,512 shares 502,512$5.88M3.4%newTimeline
BIOABIOAGE LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 527,647 shares; 2024Q4: 653,374 shares; 2025Q1: 653,374 shares; 2025Q2: 653,374 shares; 2025Q3: 653,374 shares 653,374$3.84M2.22%0Timeline
RXRXRECURSION PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 595,518 shares; 2025Q1: 595,518 shares; 2025Q2: 595,518 shares; 2025Q3: 595,518 shares 595,518$2.91M1.68%0Timeline
RALLYBIO CORPRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,404,644 shares; 2024Q4: 2,404,644 shares; 2025Q1: 2,404,644 shares; 2025Q2: 2,404,644 shares; 2025Q3: 2,404,644 shares 2,404,644$1.2M0.69%0
BOLTBOLT BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 94,573 shares; 2025Q3: 94,573 shares 94,573$503K0.29%0Timeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
INOZYME PHARMA INCINOZYME PHARMA INC4,494,851$18Mshares
VIGIL NEUROSCIENCE INCVIGIL NEUROSCIENCE INC560,595$4.46Mshares
IOBTQIO BIOTECH INC864,197$1.2Mshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001012975-25-000748 base2025-11-13acceptance time not in the bulk data set